In Brief: Nasacort AQ

Executive Summary

Nasacort AQ: Rhone-Poulenc Rorer prescription nasal spray approved by FDA Sept. 26 for use in children six to 11 for the treatment of nasal symptoms of seasonal and perennial allergic rhinitis. The company had submitted a supplemental NDA for children as young as four based on data from two double-blind, placebo-controlled trials involving 538 children ("The Tan Sheet" Oct. 28, 1996, In Brief). The triamcinolone acetonide nasal spray, which already carries an indication for allergy sufferers over 12, has been mentioned as an Rx-to-OTC switch candidate. An OTC version would be marketed by Novartis Consumer Health under a 1994 agreement between Rhone-Poulenc and Ciba...